Your Good Partner in Biology Research

Human Vascular Endothelial cell Growth Factor C,VEGF-C ELISA KIT

  • 中文名称:
    人血管内皮细胞生长因子C(VEGF-C)酶联免疫试剂盒
  • 货号:
    CSB-E04759h
  • 规格:
    96T/48T
  • 价格:
    ¥3200/¥2500
  • 其他:

产品详情

  • 产品描述:
    CUSABIO人血管内皮细胞生长因子C(VEGF-C)酶联免疫检测试剂盒(货号:CSB-E04759h),采用双抗体夹心法原理实现定量检测,适用于血清、血浆及经适当前处理的组织匀浆样本分析。VEGF-C作为血管内皮生长因子家族成员,在淋巴管生成、血管重塑及肿瘤转移等生物学过程中发挥关键调控作用,是肿瘤微环境、心血管疾病及炎症机制研究的重要靶标。试剂盒灵敏度达15.6 pg/mL,检测范围覆盖15.6-1000 pg/mL,可在3.5小时内完成检测流程,包含预包被抗体的96孔板、高纯度重组蛋白标准品、HRP标记检测抗体及TMB显色系统等核心组分,支持细胞培养上清、动物模型样本及临床前研究样本中VEGF-C蛋白表达水平的精准量化。该试剂盒适用于基础科研领域,如肿瘤生物学研究中转移机制探索、心血管疾病模型中的血管生成评估,以及药物开发过程中靶向治疗效能的体外检测,为研究者提供稳定可靠的实验工具。
  • 别名:
    Flt 4L ELISA Kit; Flt4 ligand ELISA Kit; FLT4 ligand DHM ELISA Kit; Flt4-L ELISA Kit; Flt4L ELISA Kit; Vascular endothelial growth factor C ELISA Kit; Vascular endothelial growth factor related protein ELISA Kit; Vascular endothelial growth factor-related protein ELISA Kit; VEGF C ELISA Kit; VEGF-C ELISA Kit; Vegfc ELISA Kit; VEGFC_HUMAN ELISA Kit; VRP ELISA Kit
  • 缩写:
  • Uniprot No.:
  • 种属:
    Homo sapiens (Human)
  • 样本类型:
    serum, plasma, tissue homogenates
  • 检测范围:
    15.6 pg/mL-1000 pg/mL
  • 灵敏度:
    3.9 pg/mL
  • 反应时间:
    1-5h
  • 样本体积:
    50-100ul
  • 检测波长:
    450 nm
  • 研究领域:
    Cancer
  • 测定原理:
    quantitative
  • 测定方法:
    Sandwich
  • 精密度:
    Intra-assay Precision (Precision within an assay): CV%<8%
    Three samples of known concentration were tested twenty times on one plate to assess.
    Inter-assay Precision (Precision between assays): CV%<10%
    Three samples of known concentration were tested in twenty assays to assess.
  • 线性度:
    To assess the linearity of the assay, samples were spiked with high concentrations of human VEGF-C in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
     SampleSerum(n=4)
    1:1Average %100
    Range %96-105
    1:2Average %92
    Range %87-99
    1:4Average %95
    Range %90-101
    1:8Average %92
    Range %88-96
  • 回收率:
    The recovery of human VEGF-C spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample TypeAverage % RecoveryRange
    Serum (n=5) 9994-106
    EDTA plasma (n=4)9084-96
  • 标准曲线:
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    pg/mlOD1OD2AverageCorrected
    10002.575 2.543 2.559 2.446
    5001.880 1.776 1.828 1.715
    2501.051 1.034 1.043 0.930
    1250.613 0.587 0.600 0.487
    62.50.387 0.371 0.379 0.266
    31.20.235 0.226 0.231 0.118
    15.60.169 0.158 0.164 0.051
    00.115 0.111 0.113  
  • 数据处理:
  • 货期:
    3-5 working days

产品评价

靶点详情

  • 功能:
    Growth factor active in angiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. May function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates KDR/VEGFR2 and FLT4/VEGFR3 receptors.
  • 基因功能参考文献:
    1. A possible mechanism has been proposed of the TGF-beta-VEGF-C pathway in which TGF-beta promotes VEGF-C production in tubular epithelial cells, macrophages, and mesothelial cells, leading to lymphangiogenesis in renal and peritoneal fibrosis. (Review) PMID: 30142879
    2. The mutation induced skipping of exon 2 of VEGFC resulting in a frameshift and the introduction of a premature stop codon (p.Ala50ValfsTer18). The mutation leads to a loss of the entire VEGF-homology domain and the C-terminus. PMID: 30071673
    3. VEGFR-3 and CAV3 expression demonstrated immunohistochemically in SMCs of the tunica media of SV grafts predicted their early restenosis in triple-vessel CAD patients. CAV2 protein expression in SMCs of ITA grafts indicated the risk of early graft failure both in double-vessel and triple-vessel CAD subjects. PMID: 29557990
    4. VEGF-C expression and secretion in gastric cancer is downregulated by kallistatin. PMID: 29243194
    5. Concomitant high expression of survivin and VEGF-C is closely associated with LNM status of PTC patients, which suggests their cooperation in the metastatic process. PMID: 29578160
    6. TNFSF15, a cytokine mainly produced by blood endothelial cells, facilitates tumor lymphangiogenesis by upregulating VEGFC expression in A549 cells. PMID: 29890027
    7. serum levels not elevated in patients with erythrodermic mycosis fungoides/Sezary syndrome PMID: 28925057
    8. SPARC expression was inversely associated with the degree of malignancy and it had a negative correlation with VEGF-C and VEGF-D expression. Results suggest SPARC might function as a tumor suppressor inhibiting angiogenesis and lymphangiogenesis in ovarian cancer by reducing the expression of VEGF-C and VEGF-D. PMID: 29075785
    9. VEGF-A/VEGF-C analysis showed higher positivity in metastatic nodes and higher positivity in the surrounding negative nodes from positive cases in comparison with nonmetastatic patients. PMID: 28984690
    10. this study shows that decidual NK cells facilitate the interaction between trophoblastic and endothelial cells via VEGF-C and HGF PMID: 28653669
    11. Lymphangiogenesis during tubulointerstitial fibrosis to be associated with increased expression of CTGF and VEGF-C in human obstructed nephropathy as well as in diabetic kidney disease. vitro, CTGF induced VEGF-C production in HK-2 cells, while CTGF siRNA suppressed transforming growth factor beta1-induced VEGF-C upregulation. PMID: 28545716
    12. study is the first to describe the mechanism of leptin-promoted lymphangiogenesis by upregulating VEGF-C expression in chondrosarcomas. PMID: 27345723
    13. Retroperitoneal tumour progression in EOC patients is associated with high VEGF-C expression. PMID: 28591727
    14. Mechanistic investigations indicated that BDNF facilitated VEGF-C-dependent lymphangiogenesis through the MEK/ERK/mTOR signaling pathway. PMID: 28771226
    15. Results has shown that VEGF-C was highly expressed in non-small cell lung cancer (NSCLC) tissues and metastatic lymph nodes. VEGF-C expression levels was significantly correlated with lymph node metastasis in NSCLC. Along with CXCR4, VEGF-C might synergically promote lymphatic metastasis in lung cancer and might be a clinical predictor of lymph node metastasis in NSCLC patients. PMID: 28925100
    16. CXCR4, CCR7, VEGF-C and VEGF-D expression might have synergistic effects on the lymph node metastasis in patients with cervical cancer. PMID: 28535405
    17. prolactin induction of VEGF-C and Runx2 was inhibited partly by Carboxypeptidase-D inhibitors, implicating nitric oxide , produced by PRL-regulated Carboxypeptidase-D, in breast cancer progression PMID: 28364216
    18. Study is the first to describe the mechanism of bFGF-promoted lymphangiogenesis by upregulating VEGF-C expression in chondrosarcomas. PMID: 27229532
    19. eIF4E promoted cholangiocarcinoma cell metastasis by up-regulating the expression of VEGF-C, MMP-2 and suppressing E-cadherin expression. PMID: 27907907
    20. High expression of VEGF-C in the primary tumour may be a good determinant for detection of occult tumour cells in the lymph nodes of OSCC cases. PMID: 27417330
    21. document for the first time that CCL5 induces tumor lymphangiogenesis by the induction of VEGF-C in human cancer cells. PMID: 27166194
    22. Data suggest that the BRG1/STAT3/VEGFC in tumor-associated lymphangiogenesis might lead to the discovery of novel therapeutic targets in the treatment of cancers with BRG1 loss of function. PMID: 27145366
    23. Studied the effect of recombinant human vascular endothelial growth factor (VEGF)-C on lymphangiogenesis, inflammation, and fibrosis in the mouse kidney using the unilateral ureteral obstruction (UUO); lymphangiogenesis was significantly induced in the UUO+VEGF-C group. In lymphatic endothelial cells, VEGF-C increased the activity and proliferation of such cells and expression of VCAM-1. PMID: 29083411
    24. This study reports that human dendritic cells produce VEGF-C, a cytokine with potent pro-lymphangiogenic activity when stimulated with IFN-gamma PMID: 26987844
    25. Association of coexpressed high levels of VEGF-C and active MMP-9 with lymphatic spreading and local invasiveness of Papillary thyroid carcinoma (PTC) suggests their potential usefulness as predictive biomarkers of aggressive PTC behavior. PMID: 27806941
    26. Data show that VEGF-C, VEGF-D, and VEGFR-3 were expressed in a substantial percentage of breast carcinomas. PMID: 28791841
    27. By treating LECs with VEGF-C156S and analyzing subsequent changes in gene expression, we identified several 'immediate early' transcription factors that showed a rapid transient upregulation VEGFR-3 stimulation. these results reveal an important and unanticipated role of HOXD10 in the regulation of VEGFR-3 signaling in lymphatic endothelial cells, and in the control of lymphangiogenesis and permeability. PMID: 27199372
    28. In colon cancer samples, there was a positive correlation between the expression of integrin alpha4 and VEGF-C. Integrin alpha4 and VEGF-C were significantly associated with the clinicopathological parameters (LMVD, Duke's stage, and lymph node metastasis). patients with high integrin alpha4 or VEGF-C expression had significantly shorter overall survival and tumor-free survival time. PMID: 26917449
    29. High VEGFC expression is associated with angiogenesis and lymphangiogenesis. PMID: 27852824
    30. Adiponectin promoted VEGF-C expression and secretion in human chondrosarcoma cells. PMID: 27252405
    31. Study showed that VEGF-C levels are high in hypervolemic and low in euvolemic (and hypovolemic) chronic kidney disease patients; serum VEGF-C levels were significantly correlated with bioimpedance spectroscopy measurements PMID: 28471955
    32. Taken together, we suggest that ELK3 is an upstream regulator of the NF-kappaB signaling pathway, the inhibition of which leads to the suppression of peritumoral lymphatic vessel development, possibly due to a low VEGFC expression. PMID: 28188790
    33. These results indicate that VEGF-C-induced MSC osteogenesis is mediated through VEGFR2 and VEGFR3, and followed the activation of the ERK/RUNX2 signaling pathway. PMID: 28163024
    34. Overexpression of vascular endothelial growth factor C (VEGF-C) in Kazakh esophageal squamous cell carcinoma (ESCC) was significantly associated with gender, depth of tumor invasion, lymph node metastasis and tumor clinical stage. PMID: 27939650
    35. This paper quantifies the lymphatic microvessel density (LMD) in benign and malignant salivary gland tumors and analyzes the relationship between LMD and tumor expression of vascular endothelial growth factors C (VEGF-C) and the proliferative index. PMID: 27229879
    36. KAI1-induced decreases in VEGFC expression are mediated via Src/STAT3 signaling pathways in pancreatic cancer cells. PMID: 27082851
    37. The results of this study suggest that the more aggressive biological behavior of squamous cell carcinoma of the tongue in young patients may be related to a higher expression of VEGF-C. PMID: 27876236
    38. This study suggests that NRP1 expression and LVD are independent factors that are likely to predict the risk of LN metastasis in squamous cell carcinoma (SCC)of the tongue, whereas the expression of VEGFC, VEGFR3, CCR7, and SEMA3E are nonindependent predictive factors PMID: 27666723
    39. High expression of VEGFC is associated with peritoneal dissemination in gastric cancer. PMID: 26621525
    40. TNF-alpha mediates VEGF-C expression, which plays a critical role in the pathogenesis of pterygia. PMID: 27314284
    41. a potential link between the upregulation of Syk and VEGF-C expression and lung adenocarcinoma. PMID: 27461624
    42. The summarizes the structure and function features of pathway-related molecules of VEGFC/D-VEGFR3/NRP2 axis, stages of various tumors and their molecular mechanisms and significances in tuthe expression changes of these molecules in different anatomic organs or histopathologic types or development lymphatic metastasis. PMID: 27527412
    43. Data show that WNT1-inducible signaling pathway protein-1 (WISP)-1/CCN4 expression was correlated with vascular endothelial growth factor-C (VEGF-C) expression in Oral squamous cell carcinoma (OSCC) specimens. PMID: 26824419
    44. VEGF-C overexpression shows an unfavorable prognosis for EC patients. PMID: 27540974
    45. FIGO stage (P < 0.0001), tumor grade (P < 0.0001), lymph node metastasis (P < 0.0001), serum VEGF-C concentration (P = 0.0001), and ascites VEGF-C concentration (P < 0.0001) were significantly correlated with overall survival in ovarian cancer. PMID: 23473018
    46. Our data suggested that IL-6 mediates the singnal pathway of JAK-STAT3-VEGF-C promoting the growth, invasion and lymphangiogenesis in gastric cancer PMID: 26750536
    47. The most extensively accepted signaling pathways promoting lymphangiogenesis in tumors include the secreted lymphangiogenic proteins: VEGF-C and VEGF-D, and their cognate receptor on lymphatic endothelium VEGF receptor-3 (VEGFR-3). PMID: 26706909
    48. the concurrent high expression of VEGF-C and NRP2 is predictive of the unfavorable prognosis in glioblastoma. PMID: 26753562
    49. a significant decrease in miR101 levels, accompanied with an increased expression of vascular endothelial growth factor (VEGF)C in cisplatinresistant SGC7901 gastric cancer cells. PMID: 26573417
    50. MTA1 is up-regulated in CRC; its expression is inversely associated with lymphatic metastases and the expression of VEGFC, VEGFD and VEGFR3 PMID: 26543080

    收起更多

  • 相关疾病:
    Lymphedema, hereditary, 1D (LMPH1D)
  • 亚细胞定位:
    Secreted.
  • 蛋白家族:
    PDGF/VEGF growth factor family
  • 组织特异性:
    Spleen, lymph node, thymus, appendix, bone marrow, heart, placenta, ovary, skeletal muscle, prostate, testis, colon and small intestine and fetal liver, lung and kidney, but not in peripheral blood lymphocyte.
  • 数据库链接:

    HGNC: 12682

    OMIM: 601528

    KEGG: hsa:7424

    STRING: 9606.ENSP00000280193

    UniGene: Hs.435215